@Guzz In response to the following comment in your post:"So -...

@Guzz

In response to the following comment in your post:

"So - based on the above - I read it that its in Acadia's best interests to assist Neuren for NNZ2591 development (for Rett and Fragile X trials), whereby Neuren will receive the same royalties based on the existing Daybue milestone framework."

A couple of points to consider:

1) As you point out, NEU has granted Acadia an "exclusive worldwide licence for NNZ-2591 solely in Rett and Fragile X". I recall Jon mentioning in one or more of the subsequent investor webinars that it will be up to Acadia to decide if and when they will ever use NNZ-2591 in a trial for Rett or Fragile-X. Acadia will have to fund, manage and execute all aspects of any such trials. Jon also said that NEU's role would be only to share its own 2591 experience and data with Acadia if and when when required.

2) NEU and Acadia have a joint steering committee that meets regularly to oversee and govern contract and relationship management matters. It is written into the contracts and Jon confirmed that to me some months ago.